Agilent Technologies (NYSE:A) Price Target Increased to $87.00 by Analysts at UBS Group

Agilent Technologies (NYSE:A) had its target price hoisted by UBS Group from $84.00 to $87.00 in a research note released on Friday morning, BenzingaRatingsTable reports. The firm currently has a neutral rating on the medical research company’s stock.

A number of other brokerages have also weighed in on A. Royal Bank of Canada initiated coverage on Agilent Technologies in a research note on Tuesday, April 28th. They issued a sector perform rating on the stock. Zacks Investment Research upgraded shares of Agilent Technologies from a sell rating to a hold rating and set a $89.00 price objective on the stock in a research report on Friday, February 21st. Wells Fargo & Co increased their price target on shares of Agilent Technologies from $82.00 to $95.00 and gave the stock an overweight rating in a report on Friday. Stifel Nicolaus dropped their price objective on shares of Agilent Technologies from $85.00 to $73.00 and set a hold rating for the company in a report on Thursday, April 2nd. Finally, Barclays reduced their target price on Agilent Technologies from $85.00 to $76.00 and set an equal weight rating on the stock in a research note on Thursday, March 26th. Eleven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Agilent Technologies presently has an average rating of Hold and an average target price of $85.75.

Shares of NYSE:A traded up $4.23 during mid-day trading on Friday, hitting $84.98. The company had a trading volume of 5,063,071 shares, compared to its average volume of 2,117,454. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.64 and a quick ratio of 1.27. Agilent Technologies has a one year low of $61.13 and a one year high of $90.64. The firm has a fifty day moving average price of $77.33 and a 200 day moving average price of $79.96. The company has a market capitalization of $25.00 billion, a PE ratio of 39.16 and a beta of 1.10.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Thursday, May 21st. The medical research company reported $0.71 EPS for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.10. Agilent Technologies had a return on equity of 20.75% and a net margin of 13.04%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period last year, the business posted $0.71 earnings per share. Agilent Technologies’s revenue was up .2% on a year-over-year basis. Research analysts expect that Agilent Technologies will post 2.95 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Tuesday, June 30th will be paid a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.85%. The ex-dividend date of this dividend is Monday, June 29th. Agilent Technologies’s payout ratio is 23.15%.

In related news, VP Mark Doak sold 3,494 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $83.81, for a total value of $292,832.14. Following the sale, the vice president now directly owns 135,678 shares of the company’s stock, valued at $11,371,173.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael R. Mcmullen sold 13,603 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $78.72, for a total value of $1,070,828.16. Following the transaction, the chief executive officer now owns 529,245 shares in the company, valued at approximately $41,662,166.40. The disclosure for this sale can be found here. Insiders have sold a total of 43,929 shares of company stock valued at $3,476,727 in the last three months.

Several institutional investors and hedge funds have recently bought and sold shares of the company. NuWave Investment Management LLC lifted its position in shares of Agilent Technologies by 1,116.1% in the 1st quarter. NuWave Investment Management LLC now owns 377 shares of the medical research company’s stock worth $27,000 after purchasing an additional 346 shares during the period. First Bank & Trust bought a new position in Agilent Technologies in the fourth quarter worth about $29,000. Citizens Financial Group Inc RI lifted its holdings in Agilent Technologies by 260.0% in the fourth quarter. Citizens Financial Group Inc RI now owns 360 shares of the medical research company’s stock worth $31,000 after buying an additional 260 shares during the period. Ameritas Investment Company LLC boosted its position in Agilent Technologies by 169.1% during the 1st quarter. Ameritas Investment Company LLC now owns 444 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 279 shares in the last quarter. Finally, FinTrust Capital Advisors LLC boosted its position in Agilent Technologies by 450.7% during the 4th quarter. FinTrust Capital Advisors LLC now owns 380 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 311 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Further Reading: Stop Order Uses For Individual Investors

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.